Abstract: Immiscible phases, particularly polar and non-polar liquids, semi-solids or solids, are combined in a composition where one is finely dispersed throughout the other without reliance upon emulsifying agents to either create or stabilize the dispersion. The composition is formed by placing the discontinuous phase in the pores of solid inert porous particles, in which the pores are in the form of an interconnected network open to the exterior of the particles to provide interfacial contact with the continuous phase. The particles are then dispersed in the continuous phase. The concept is applicable to oil-in-water and water-in-oil type dispersions, and the disadvantages and shortcomings of emulsifying agents are entirely avoided.

Abstract: Articles for use in contact with animal tissue, such as surgical and first aid supplies, health care products and personal hygiene products, are dusted with microspheres for lubricating purposes or for the application of diffusible adjuvants. In the latter case, the microspheres are porous, with a continuous network of pores open to the exterior of the particles, permitting outward diffusion of the adjuvants at a controlled rate depending on pore size. The adjuvants include such substances as biologically active substances, deodorants, flavors, fragrances, and liquid lubricants.

Abstract: Transdermal drug delivery systems comprise a backing or enclosure having a matrix layer which incorporates a drug and a percutaneous enhancer for the drug. The percutaneous enhancer and/or drug will be contained within polymeric particles dispersed through the matrix layer, where the polymeric particles define pore networks which are sized to release the enhancer and/or drug into the matrix layer at rate(s) selected to provide for a desired rate of drug penetration. By isolating the enhancer within the polymeric particles, adverse interactions between the enhancer and the matrix layer and/or the drug can be minimized. Moreover, the release rate of the enhancer into the matrix layer can be carefully controlled, which in turn controls the penetration rate of the drug into the treated host.

Abstract: Melanin compositions include a melanin pigment incorporated within polymeric particles, usually within an internal pore network defined by a polymeric particle matrix. The melanin compositions may be produced by in situ oxidation of melanin precursors within the pore network, or by absorption of a melanin pigment in a suitable vehicle or carrier. The melanin compositions are found to display enhanced absorbance of ultraviolet radiation and better cosmetic attributes when compared to melanin pigments which are not incorporated in such a polymeric particle matrix.

Abstract: Melanin compositions include a melanin pigment incorporated within an internal pore network defined by a polymeric particle matrix. The melanin compositions may be produced by in situ oxidation of melanin precursors within the pore network, or by absorption of a melanin pigment dispersed in a suitable vehicle or carrier. The melanin compositions are found to display enhanced absorbance of ultraviolet radiation when compared to melanin pigments which are not incorporated in such a polymeric particle matrix.

Abstract: A novel spherical implant pellet containing estradiol, estradiol benzoate, or mixtures thereof as the sole active ingredients which exhibits a substantially constant drug release rate over a timer period and substantially abrupt termination of drug release at the end of the time period is prepared which has an inert spherical core of a diameter of about 2-10 mm and a uniform coating of about 0.05-1 mm completely covering the core, the coating comprising about 5-99% suitable carrier and 1-95% drug. A drug may be administered at a constant rate over a chosen period by implanting the novel pellet and the release is substantially abruptly terminated at the end of said period without removing the pellet.

Abstract: A novel spherical implant pellet containing estradiol, estradiol benzoate, or mixtures thereof as the sole active ingredients which exhibits a substantially constant drug release rate over a timer period and substantially abrupt termination of drug release at the end of the time period is prepared which has an inert spherical core of a diameter of about 2-10 mm and a uniform coating of about 0.05-1 mm completely covering the core, the coating comprising about 5-99% suitable carrier and 1-95% drug. A drug may be administered at a constant rate over a chosen period by implanting the novel pellet and the release is substantially abruptly terminated at the end of said period without removing the pellet.

Abstract: This application describes analgesic formulations including d 2-(6-methoxy-2-naphthyl)propionic acid, or a pharmaceutically acceptable salt or ester thereof, in combination with at least one central nervous system active analgesic compound. Analgesic activity of the combination is greater than that obtained with either of the components alone, thus demonstrating enhanced analgesia which can be obtained therewith.

Abstract: This application describes analgesic formulations including d 2-(6-methoxy-2-naphthyl)propionic acid, or a pharmaceutically acceptable salt or ester thereof, in combination with at least one central nervous system active analgesic compound. Analgesic activity of the combination is greater than that obtained with either of the components alone, thus demonstrating enhanced analgesia which can be obtained therewith.